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Background. Treatment for Burkitt' slvtnnhoma 
Children's Hospital has ev()lved from the use of aggressive 
surgery and less intensive chemotherapy to a conservative 
surgical approach with more intensive chemotherapy. 
Methods. The stu<iy was a retrospective folder revi~ of 
patients diagnosed with Burkitt's lymphoma a.t RCCHbetWe(m 
1984and 2004. 
Results. Ninety~two childrenwere.treated for Burkitt's 
lymphoma. atRCCHbetween 1984 and 2004. Therewere 10 
patients with group A or fully resected disease, 52 with group 
B or extensive localised disease, and 30 with dissemination 
to the bone marrow and/ or central nervous system or group 
Cdisease. Protocoll(less intensive chemotherapy based on 
the COMP regimen) was used froml984, with protocol2 
(more intensive chemotherapy based on the LMB regimen) 
introduced in 1988 for group C disease, .1991. for group B 
Burkitt's lymphoma (BL) is the third most common solid 
tumour occurring in children in Africa, being exceeded only 
by brain tumours and Wilms' tumour. This is due to the high 
incidence of endemic BL (estimated at 40- 100 per million 
per year in children under 15)1 in the 'lymphoma belt', 
an area from 10° north to 10° south of the equator, which 
corresponds roughly with the malaria belt. The ability of 
the Epstein-Barr virus (EBV) to transform lymphocytes by 
inducing the translocations typically found in BL appears to 
be augmented by malarial parasitaemia. These translocations 
involve the c-Myc oncogene on chromosome 8 and one of the 
immunoglobulin heavy or light chain loci on chromosomes 2, 
14 and 22. 
The endemic form found in these areas is characterised by 
a jaw mass (58%), with or without abdominal disease (58%). 
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disease artd·1996for group A disease. OverallS-year survival 
increased from 20% With protocol lto 66% with protocol 2 for 
group C disease, and from 76.5% with protocoll to 88.2% with 
protocol2 for group B disease, There were more admissions 
for neutropel,lic fever in patients on protocol 2 and more 
episqdes oh.nucositis, ~nd these pat.ientsrequired 111ore red cell 
ancl platelet transfusions.Withamoreco~servative surgical 
approach,biopE?y lar:gely replaced iittempts to partiallyresed 
the tumour at primary stngery, and there was a consequent 
declitte in surgical.complications. 
Conclusions. Intensive chemotherapy with protocol 2 has 
resulted in improved survival for group C and group B 
patients, but With more morbidity. Protocoll, which is less 
intensiveWit);ll~~sm()rbidity, remains a viable strategy for 
group A and group B disease in resource-poor settings. 
S AfrMed J 2006; 96!950"954. 
Bone marrow involvement is rare (7%) but central nervous 
system involvement is more common (19%). The sporadic form 
found throughout the Western world typically presents as an 
abdominal mass (88%). Bone marrow involvement is more 
common than in the endemic form (21 %) while jaw masses 
(14%) and central nervous system involvement (11 %) are less 
common.2 In South Africa most cases fall into the sporadic 
group. 
This review examines the evolution in treatment for BL at 
Red Cross War Memorial Children's Hospital (RCCH) between 
1984 and 2004. With the use of protocol1 (Pl) and aggressive 
surgery during the 1980s, excellent results were being achieved 
for patients with extensive localised disease. This was however 
at the cost of considerable surgical morbidity; and the outcomes 
of patients with bone marrow and central nervous system 
involvement remained dismal. A more intensive regimen, 
protocol2 (P2), was introduced during the late 1980s, first for 
those with disseminated disease, and then for localised disease. 
At the same time a consensus was emerging internationally 
that with more intensive chemotherapy, debulking of large 
abdominal tumours was no longer necessary.3 In addition, 
relook surgery to assess disease response after induction 
chemotherapy could be reserved for patients where residual 
disease was suspected. 
We undertook this review of patients treated for BL at 
RCCH in order to establish whether our patients with 
disseminated disease have a superior survival with P2 and 
.-------
whether the outcome for extensive localised disease improved 
despite the increased toxicity associated with more intensive 
chemotherapy. 
Methods 
The study was a retrospective folder review of patients 
diagnosed with BLat RCCH between 1984 and 2004. Patients 
were identified from the Oncology Registry of the RCCH 
Haematology-Oncology Service. Data on each patient were 
collected from the hospital notes. Four HIV-positive patients 
presented with BL between 2003 and 2004. These patients were 
treated with antiretroviral therapy and an alternative protocol, 
and were excluded from this study. 
The diagnosis of BL was made on histological examination. 
Upon diagnosis, staging for each patient involved bilateral 
bone marrow biopsy, and examination of the cerebrospinal 
fluid (CSF). Chest X-ray and ultrasound of the abdomen were 
mandatory; and CT scans of the head, chest or abdomen were 
obtained where indicated. 
During the early years of the study; tumours were partially 
or completely resected where possible. More recently this was 
gradually superseded by biopsy (via laparotomy or laparoscopy) 
for all but small localised intra-abdominal tumours. Definitive 
surgery was performed in patients presenting with intraluminal 
complications such as intussusception. When the diagnosis 
could be made from the bone marrow, or cerebrospinal, pleural 
or ascitic fluid, surgical biopsy was not performed. 
The patients were divided into groups according to the 
risk stratification devised by the French Paediatric Oncology 
Society' (Table I). 
Two chemotherapy protocols were used, P1 based on the 
COMP arm of United States Children's Cancer Group protocol 
CCG-551,5 and P2 based on the French Paediatric Oncology 
Society protocol LMB-89 (Fig. 1).6 P2 was introduced for group 
C patients in 1988, for group B patients in 1991, and for group 
A patients in 1996. 
All patients were treated with allopurinol, hyperhydration 
and urinary alkalinisation at the commencement of induction 
chemotherapy to prevent tumour lysis syndrome. Granulocyte 
colony stimulating factor at a dose of 5 p.g/kg per day for 
14 days was used in an attempt to shorten the period of 
neutropenia following intensive chemotherapy in P2. 
Originally, second-look laparotomy was often performed 
as part of the review of advanced abdominal disease after 
induction chemotherapy. Later, it was reserved for cases where 
there was clinical or radiological suspicion of residual disease. 
Relapse-free and overall survival were estimated by the 
method of Kaplan and Meier. Survival analysis was performed 
using Statistica 6.1 (Statsoft, Inc. 1984- 2003). 
September 2006, Vol. 96, No.9 SAM} 
Table J. ·Risk stratification for Burkitt's lymphoma (devised 





Complete surgical resection of stage I or 
abdominal stage II 
All patients not eligible for group A or 
groupe 
Any tumour with eNS involvement 
Any tumour With more than 25% blasts in 
the bone marrow 
Ninety-two HIV-negative patients with BL were admitted to 
RCCH between January 1988 and December 2004. There were 
64 males and 28 females, with a male/female ratio of 2.3:1. The 
patients ranged in age from 1.6 to 13.95 years, with a median 
age of 5.53 years. The two treatment cohorts had an almost 
identical demographic profile. 
Seventy patients (76%) presented with symptoms related to 
abdominal disease, including pain, distension and vomiting. 
Nine patients presented with a jaw mass, and 6 with a neck 
mass. Four presented with generalised adenopathy and bone 
pain, and 3 with paresis due to paraspinal masses. 
At diagnosis 77 (83.6%) were found to have abdominal 
disease. Fifty-nine had bowel involvement, including 10 with 
intussusception. Twenty patients had disease involving the 
liver and 10 had renal involvement. Thirteen patients had 
involvement of the uterus, ovary or bladder and 1 patient had 
involvement of the testes. Twenty-five patients had ascites. 
Nine patients (9.8%) had jaw masses and 12 patients had 
pleural effusions. 
Fifteen patients (16.3%) had central nervous system 
involvement at diagnosis. Three had paraspinal masses, 4 had 
central nervous system masses with cranial nerve palsies, and 
11 had blasts in the cerebrospinal fluid. Twenty-five patients 
(27.2%) had more than 25% blasts in the bone marrow. Ten of 
these patients also had central nervous system involvement. 
In all, 30 patients (32.6%) had group C disease; 15 with 
leukaemia, 5 with central nervous system involvement and 
10 with both. Ten patients (10.9%) had group A disease; 9 had 
fully resected localised abdominal lymphomas and 1 cervical 
adenopathy. The other 52 patients (56.5%), including 6 with 
less than 25% blasts in the bone marrow, had group B disease. 
There were more group C patients in the P2 cohort (40% for 
P2 v. 17% for P1), and less group A patients (5% v. 23%), due to 
the staggered introduction of this protocol. Both cohorts had a 
similar percentage of group B patients (55% v. 60%). 
All group A patients had complete resection. Thirteen 
(61.9%) of the abdominal group Band C patients treated with 
P1 but only 8 (15.7%) of those treated with P2 had partial 
resection. Second-look laparotomy was performed for 10 
Infectious complications 
TB represents a significant problem. During the period 
1996-2004, the incidence of TB was 7/72 (9.7%) in our 
transplant patients. Presentation was 10 months to 8 years 
post transplant with symptoms of fever and cough in all and 
weight loss in most. No patients were on prophylaxis. With 
the exception of one renal case, the rest all had pulmonary TB 
with pericardia! involvement in 2 cases. Immunosuppression 
at the time of diagnosis consisted of cyclosporin, azathioprine 
and prednisone. Diagnosis was made on finding acid-fast 
bacilli using a combination of sputum, nasogastric aspirate 
and bronchial lavage. In one case, a fine-needle aspirate of the 
lung produced the acid-fast bacilli. All the cases were typically 
mycobacterium TB and fully sensitive to rifampicin and 
INH. Three cases had had an increased dose of steroids in the 
preceding 3 months. An increased cyclosporin dose (up to 5 
times) was required once starting the rifampicin. All cases were 
successfully treated with no loss of patient or graft. 
Fatal CMV infection was seen in a 13-year-old girl with 
renal dysplasia and Fanconi's anaemia who received a 
CMV-mismatched organ (donor CMV positive: recipient 
CMV negative) in February 2001. Prophylactic intravenous 
ganciclovir was given for 2 weeks, but unfortunately she 
developed a pneumonia requiring ventilation 11 months later 
and died of CMV pneumonia. 
EBV-driven post-transplant lymphoproliferative disorder 
(PTLD) was seen in 1 renal transplant who presented with a 
nodal mass in his inguinal region. Immunosuppression was 
reduced and ganciclovir and rituximab (anti-CD 20 agent) were 
given together with chemotherapy. Therapy remains successful 
together with preserved renal function. 
Other serious infections in this group of patients have 
included disseminated varicella with transverse myelitis, 
Pneumocystis jiroveci pneumonia and cat scratch disease 
(Bartonella henselae). All were treated successfully and retained 
their grafts. 
Vaccinations 
Audit of vaccination status in a group of 32 cases with age 
range 93-225 months (mean 148 months) reviewed post 
transplant found protective immunity to hepatitis A (53% 
patients), hepatitis B (19% patients) and varicella (72% 
patients). 
Adolescent transplant transition 
mJ We have had difficulty with transition of adolescents to adult 
units in the last 10 years with 5 adolescents having lost their 
grafts and 2 dying within 1 year of transfer despite adequate 
renal function at time of transfer. We have good 1- and 5-year 
graft and patient survival but our long-term outcome in the 
adolescent age group is significantly worse than in younger 
transplant recipients, as is reported universally. 
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Discussion 
Paediatric transplantation poses numerous challenges, not only 
the conventional problems of acute rejection and infection, but 
also technically creative surgery to accommodate the significant 
size range (our group ranged from 8 kg to 63 kg) of paediatric 
patients. There may be further challenges in a developing 
country including difficult social circumstances, poor HLA 
matching (68% of our patients had 5 or more mismatches) as 
well as a limited number of donors exacerbated by the high 
incidence of HIV infection. In order to try and increase our 
donor pool, we may need to expand the current pool of living 
related donors (24%) beyond just the parents and potentially 
also consider non-heart-beating donors. 
Whereas previously acute rejection was our biggest concern, 
this has now become easier to manage, by using the newer 
immunosuppressant agents including induction with IL2 
receptor blockers. Our acute rejection rate has reduced to 18.8% 
using 2 initial doses of IL2 receptor blockers (both basiliximab 
and daclizumab used in 2-dosing regimen). Despite the initial 
cost of this form of therapy, these agents have allowed us to 
use an overall cheaper immunosuppressive protocol (such 
as cyclosporin and azathioprine) in our setting where cost 
containment is important. 
However, the consequences of increased immunosuppression 
and reduced rejection are increased infection; this is highlighted 
by problems such as CMV infection or EBV-driven PTLD. This 
is particularly a problem in the young patient with no previous 
CMV or EBV exposure who receives a donor organ-recipient 
mismatch. The advent of qualitative and, more recently; 
quantitative polymerase chain reaction (PRC) testing will have 
a significant impact on both monitoring and management 
of these viruses. Intravenous ganciclovir is costly and 
inconvenient and hopefully prophylaxis will be made easier 
with the introduction of the oral valganciclovir form. As yet no 
vaccines are available for these two viruses. 
TB is endemic in our region - our rate of TB in paediatric 
transplant patients was 9.7%- and together with HIV infection, 
raises issues of drug resistance, choice and duration of 
prophylactic agents.6 Our patients developed TB 10 months 
to 8 years post transplant and it would thus be futile using 
prophylaxis for TB in the first 6 months only. Drug interactions 
between anti-TB drugs and immunosuppressants are also a 
concern. 
On review of the vaccination status in a small group of 
our patients, hepatitis B levels were low post transplant with 
Varicella rates best overall. Paediatric studies have shown loss 
of antibodies to vaccinations within 6 months post-transplant? 
Awareness of adequate vaccination pre-transplant, specifically 
live-attenuated vaccines, with regular post-transplant 
monitoring, is important in reducing complications from these 
infections. 
In an established paediatric programme, with 1- and 5-year 
results which are satisfactory by international paediatric 
standards, despite all the problems of a developing country, 
emphasis on long-term graft and patient survival becomes 
an important focus. In view of this, we have tried to limit 
nephrotoxicity often caused by calcineurin inhibitors by using 
renal-sparing immunosuppressants. MMF has been useful 
in reducing dosing or even ceasing calcineurin inhibitors 
completely in those with chronic allograft nephropathyB and 
we have managed to use MMF and steroids as dual therapy 
only, with stable renal function so far in 3 of our patients. 
Sirolimus has also been well described as a renal-sparing 
agent/ but we have seen a significant number of drug-
related side-effects including interstitial pneumonitis and 
thrombocytopenia with purpura. In 2 cases we have noticed 
unexplained new-onset proteinuria, which has been described 
by a few centres as a concern. · 
In those patients on calcineurin inhibitors, cyclosporin has 
been responsible for significant cosmetic effects (hirsuitism and 
gum hypertrophy). These patients have usually been changed 
to tacrolimus therapy but this has also had problems of 
diabetes in 6% of our renal transplant in which 50% were black 
paediatric patients (relatively higher incidence than that of the 
total programme which consists of 31% black patients). 
Children's growth in paediatric transplantation has received 
much attention recently and this is particularly important at a 
centre where growth hormone is not easily available. Steroids 
as immunosuppression have attracted negative press recently. 
In response to this, there have been three main approaches: (i) 
steroid elimination or avoidance in the first place12 with use 
of heavier immunosuppression such as a prolonged course of 
daclizumab; (ii) steroid withdrawal in those who had steroids 
at time of transplant;13 or (iii) steroid preservation at low 
dosing. We use the last approach using low-dose (0.05 mg/ 
kg/ day) alternate-day steroids. A recent review by Marks and 
Trompeter14 also encouraged steroid preservation to prevent 
exchanging acute rejection for infection including EBV I 
PTLD. They suggest that steroids remain superior to many 
other immunosuppressive drugs in terms of cost and past 
experience, suggesting that it may be more sensible to remove 
calcineurin inhibition. 
Long-term outcomes are greatly affected by adolescent 
issues and this is clearly seen by our results at 1 and 5 years 
compared with the group more than 7 years post transplant 
(Figs 4 and 5). This is notoriously the most difficult group 
of patients to follow up, a problem for colleagues in both 
paediatric and adult units alike, and we have this in common 
with the rest of the world.15 This is particularly problematic 
where resources are limited, with adolescent issues similar 
to those in developed countries, but different economic 
constraints resulting in patients not being offered repeat 
dialysis or transplant. 
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In response to our poor long-term graft survival in 
adolescence, we have set up a combined transplant clinic with 
our adult and paediatric team based at the adult unit. This 
includes social support in the form of psychiatrists, nurses and 
social workers. 
Challenges in the transition period include overcoming the 
fear of an unknown hospital, adjusting to a different patient/ 
doctor ratio and increased independence in terms of their own 
health care. The move is preceded by psychological input in 
the form of workshops and one-to-one interviews prior to 
transfer to the adult unit. 
We also delay the transfer to at least 16 years of age and 
often even older until patients are mature enough to do the 
transition with their independence established. Preparation of 
our younger adolescents, involving them in their own renal 
function results and medication adjustments, is also important 
with a positive goal of seeing transition to an adult unit as 
a successful 'graduation' process. A 'champion' on the adult 
service is required -be that a nurse or a doctor - so that the 
patients feel comfortable at the time of transfer by identifying 
a familiar face involved with them throughout the transition 
period. 
Other factors affecting long-term outcome also depend on 
decreasing cardiovascular risk factors by reduction of steroid 
dosing, careful attention to body mass index to prevent obesity 
and inclusion of statins where necessary. 
Despite all the challenges of a developing country, a 
successful paediatric transplant programme is possible, 
provided one is aware of all the pitfalls including infection, 
nephrotoxic drugs and adolescent transition. 
Thanks to Jeanette Raad for statistical assistance. 
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